Escherichia (e.g., Escherichia Coli, Etc.) Patents (Class 424/257.1)
  • Patent number: 10689422
    Abstract: The inventive subject matter relates to a recombinant polypeptide constructs comprising enterotoxigenic Escherichia coli fimbrial subunits. The recombinant polypeptide constructs comprise multiple subunits to the same or different ETEC fimbrial types. The constructs are useful for inclusion in immunogenic formulations for the induction of immunity against entertoxigenic Escherichia coli. The inventive subject matter also relates to the use of the recombinant polypeptide constructs in induce anti-enterotoxigenic Escherichia coli immunity.
    Type: Grant
    Filed: March 24, 2016
    Date of Patent: June 23, 2020
    Assignee: The United States of America as represented by the Secretary of the Navy
    Inventor: Stephen Savarino
  • Patent number: 10286054
    Abstract: Provided are novel methods for expressing antigens in a vaccine vector strain, a live oral vaccine designed to prevent clostridium difficile-associated disease and methods for delivering antigens to the mucosal immune system of a subject.
    Type: Grant
    Filed: October 11, 2013
    Date of Patent: May 14, 2019
    Assignee: THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS
    Inventors: Edgar C. Boedeker, Sudeep Kumar
  • Patent number: 9790257
    Abstract: A method for increasing the presentation of ETEC CS6 antigen on cell surface, comprising the step of contacting cells expressing said antigen with an aqueous solution comprising 0.6-2.2 percent phenol by weight, such that the presentation of said antigen is increased by at least 100%. A method for the manufacture of a killed whole cell vaccine for immunization against CS6-expressing ETC. Cells and vaccines obtainable by the above methods.
    Type: Grant
    Filed: January 28, 2016
    Date of Patent: October 17, 2017
    Assignee: Scandinavian Biopharma Holding AB
    Inventors: Nils Carlin, Ann-Mari Svennerholm, Joshua Tobias
  • Patent number: 9248175
    Abstract: The present invention relates to compositions and methods for disease treatment and prevention through administration of a live attenuated composition. In particular, the present invention provides compositions and methods for the treatment and prevention of urinary tract infection by administration of a live attenuated compositions lacking O-antigen ligase activity.
    Type: Grant
    Filed: April 28, 2014
    Date of Patent: February 2, 2016
    Assignee: NORTHWESTERN UNIVERSITY
    Inventors: David Klumpp, Anthony Schaeffer, Benjamin Billips
  • Patent number: 9023363
    Abstract: The present invention relates to cholera toxin CTA1 protein fragments, adjuvant compositions, and methods relating to adjuvants for vaccines. The invention also relates to using recombinant CTA1 fragments conjugated to a polypeptide containing a protein transduction domain or cell-penetrating peptide as an immunomodulator.
    Type: Grant
    Filed: October 21, 2009
    Date of Patent: May 5, 2015
    Assignee: International Vaccine Institute
    Inventors: Cecil Czerkinsky, Manki Song
  • Patent number: 9017698
    Abstract: This invention describes novel adjuvant compositions and formulations with excellent stability at refrigerated and room temperatures and up to and about 37° C. that can be produced at remarkably low costs. This invention describes novel vaccine compositions and formulations to treat and prevent urinary tract infections caused by gram-negative bacteria including Escherichia coli and multi-drug resistant E. coli. This invention also describes methods of administration of said novel vaccine compositions and formulations and methods of treatment to prevent and treat urinary tract infections caused by gram-negative bacteria including E. coli and multi-drug resistant E. coli.
    Type: Grant
    Filed: September 23, 2014
    Date of Patent: April 28, 2015
    Assignee: Sequoia Sciences, Inc.
    Inventors: Gary Eldridge, Steven M Martin
  • Patent number: 8999291
    Abstract: This invention provides isolated or recombinant polypeptides that are useful to vaccinate individuals suffering from chronic/recurrent biofilm disease or as a therapeutic for those with an existing infection. The individual's immune system will then naturally generate antibodies which prevent or clear these bacteria from the host by interfering with the construction and or maintenance of a functional protective biofilm. Alternatively, antibodies to the polypeptides can be administered to treat or prevent infection. Bacteria that cannot form functional biofilms are more readily cleared by the remainder of the host's immune system.
    Type: Grant
    Filed: March 28, 2011
    Date of Patent: April 7, 2015
    Assignees: University of Southern California, Research Institute at Nationwide Children's Hospital
    Inventors: Steven D. Goodman, Lauren O. Bakaletz
  • Publication number: 20150086591
    Abstract: This invention describes novel adjuvant compositions and formulations with excellent stability at refrigerated and room temperatures and up to and about 37° C. that can be produced at remarkably low costs. This invention describes novel vaccine compositions and formulations to treat and prevent urinary tract infections caused by gram-negative bacteria including Escherichia coli and multi-drug resistant E. coli. This invention also describes methods of administration of said novel vaccine compositions and formulations and methods of treatment to prevent and treat urinary tract infections caused by gram-negative bacteria including E. coli and multi-drug resistant E. coli.
    Type: Application
    Filed: September 23, 2014
    Publication date: March 26, 2015
    Inventors: Gary Eldridge, Steven M. Martin
  • Publication number: 20150086592
    Abstract: This invention describes novel adjuvant compositions and formulations with excellent stability at refrigerated and room temperatures and up to and about 37° C. that can be produced at remarkably low costs. This invention describes novel vaccine compositions and formulations to treat and prevent urinary tract infections caused by gram-negative bacteria including Escherichia coli and multi-drug resistant E. coli. This invention also describes methods of administration of said novel vaccine compositions and formulations and methods of treatment to prevent and treat urinary tract infections caused by gram-negative bacteria including E. coli and multi-drug resistant E. coli.
    Type: Application
    Filed: September 23, 2014
    Publication date: March 26, 2015
    Inventors: Gary Eldridge, Steven M Martin
  • Patent number: 8980279
    Abstract: The invention provides methods of treating inflammation in a specific organ or tissue of an individual. The method involves determining whether the individual has previously been infected with at least one pathogen that is pathogenic in the specific organ or tissue; and administering to the individual an anti-inflammatory composition comprising antigenic determinants, the antigenic determinants selected or formulated so that together they are specific for the at least one pathogen. The pathogen may be an endogenous or exogenous pathogen, and may further be a bacterial pathogen, a viral pathogen, a fungal pathogen, a protozoan pathogen, or a helminth pathogen.
    Type: Grant
    Filed: July 27, 2012
    Date of Patent: March 17, 2015
    Assignee: Qu Biologics
    Inventors: Harold David Gunn, Salim Dhanji, Brett Anthony Premack, Michael Tak Huai Chow
  • Publication number: 20150056246
    Abstract: The present invention relates to a probiotic cell transformed with a construct suitable to overexpress and display on the surface of the probiotic cell a fusion protein comprising at least a portion of a transport protein coupled to at least a portion of one or more antigenic proteins or peptides. Probiotic-derived vesicles displaying this fusion protein as well as methods of inducing an immune response using the probiotic cells or vesicles are also disclosed.
    Type: Application
    Filed: March 13, 2013
    Publication date: February 26, 2015
    Inventors: David A. Putnam, Joseph Rosenthal, Chung-Jr Huang, Matthew Delisa, Susana Mendez
  • Publication number: 20150024005
    Abstract: The disclosure relates to a composition added to animal feed used in combination with a vaccine to enhance the effectiveness of the vaccine. Amongst other effects, the composition raises the titer of antibodies to the vaccine.
    Type: Application
    Filed: July 30, 2014
    Publication date: January 22, 2015
    Inventors: Neil E. Forsberg, Steven B. Puntenney
  • Patent number: 8858930
    Abstract: The invention provides live, attenuated enterohemorrhagic Escherichia coli (EHEC) bacteria in which the Shiga toxin coding sequences are deleted to abolish Shiga toxin production and one or more of the nucleotide sequences for the bacterial adhesin protein intimin, the locus of enterocyte effacement encoded regulator, and the translocated intimin receptor are mutated to inactivate the activity of the encoded protein(s). This live, attenuated E. coli bacteria is used in a vaccine for reducing or inhibiting carriage and shedding of EHEC in cattle.
    Type: Grant
    Filed: October 26, 2005
    Date of Patent: October 14, 2014
    Assignees: The United States of America as Represented by the Department of Veteran Affairs
    Inventors: Chengru Zhu, Edgar Boedeker
  • Patent number: 8808706
    Abstract: The present invention concerns a composition comprising physiologically stressed Arthrospira maxima for use as a biocide and/or therapeutic. The invention also concerns a method for preventing or treating an infection or infestation of a subject by an organism, wherein the method comprises the step of administering to the subject an effective amount of a composition comprising physiologically stressed Arthrospira.
    Type: Grant
    Filed: November 3, 2005
    Date of Patent: August 19, 2014
    Assignee: Biovite Australia Pty. Ltd.
    Inventors: Kelvin Winston Duncan, Peter Owen Johnston, Ashley Michael Brown
  • Publication number: 20140199345
    Abstract: The present invention relates to immunostimulatory oligodeoxynucleotides, vectors and vaccines comprising such oligodeoxynucleotides, to their use as a medicament, to their use in preventing or combating infectious disease, to methods for the detection of such oligodeoxynucleotides and to cells to be used in these methods.
    Type: Application
    Filed: May 25, 2012
    Publication date: July 17, 2014
    Inventors: Carla Christina Schrier, Simon Ilg
  • Publication number: 20140193457
    Abstract: The present invention relates to immunostimulatory oligodeoxynucleotides, vectors and vaccines comprising such oligodeoxynucleotides, to their use as a medicament, to their use in preventing or combating infectious disease and to methods for the detection of such oligodeoxynucleotides.
    Type: Application
    Filed: May 25, 2012
    Publication date: July 10, 2014
    Inventors: Carla Christina Schrier, Simon ILG
  • Publication number: 20140186398
    Abstract: The disclosure features vaccine adjuvants comprising prokaryotic mRNA, and methods of vaccination using the adjuvants. More specifically, the disclosure provides a vaccine composition comprising a nonviable immunogen (e.g., heat-killed bacterium), a tumor antigen, or an immunogenic peptide of microbial or mammalian origin, and an adjuvant, wherein adjuvant comprises prokaryotic mRNA (e.g., bacterial mRNA), as well as the methods of using the vaccine compositions. Further disclosed are the structural features of the prokaryotic mRNA used as the adjuvants.
    Type: Application
    Filed: July 17, 2012
    Publication date: July 3, 2014
    Applicant: ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
    Inventors: Julie Magarian Blander, Leif Erik Sander
  • Publication number: 20140178436
    Abstract: A method for increasing the presentation of ETEC CS6 antigen on cell surface, comprising the step of contacting cells expressing said antigen with an aqueous solution comprising 0.6-2.2 percent phenol by weight, such that the presentation of said antigen is increased by at least 100%. A method for the manufacture of a killed whole cell vaccine for immunization against CS6-expressing ETEC. Cells and vaccines obtainable by the above methods.
    Type: Application
    Filed: September 10, 2012
    Publication date: June 26, 2014
    Applicant: SCANDINAVIAN BIOPHARMA HOLDING AB
    Inventors: Nils Carlin, Ann-Mari Svennerholm, Joshua Tobias
  • Patent number: 8758764
    Abstract: Disclosed herein are various open reading frames from a strain of E. coli responsible for neonatal meningitis (MNEC), and a subset of these that is of particular interest for preparing compositions for immunising against MNEC infections.
    Type: Grant
    Filed: February 17, 2006
    Date of Patent: June 24, 2014
    Assignees: Novartis Vaccines and Diagnostics Srl, J. Craig Venter Institute
    Inventors: Vega Masignani, Danilo Gomes Moriel, Francesco Berlanda Scorza, Nathalie Norais, Maria Rita Fontana, Mariagrazia Pizza, Laura Serino, Herve Tettelin
  • Patent number: 8709444
    Abstract: The present invention relates to compositions and methods for disease treatment and prevention through administration of a live attenuated composition. In particular, the present invention provides compositions and methods for the treatment and prevention of urinary tract infection by administration of a live attenuated compositions lacking O-antigen ligase activity.
    Type: Grant
    Filed: May 14, 2010
    Date of Patent: April 29, 2014
    Assignee: Northwestern University
    Inventors: David Klumpp, Anthony Schaeffer, Benjamin Kyle Billips
  • Patent number: 8673311
    Abstract: The present invention relates to a method of coating a spore with one or more therapeutic agents. The present invention also relates to a coated spore obtained by the method of the present invention and the use of the coated spore as a vaccine.
    Type: Grant
    Filed: September 21, 2010
    Date of Patent: March 18, 2014
    Assignee: Royal Holloway and Bedford New College
    Inventors: Simon Michael Cutting, Hong Anh Huynh
  • Publication number: 20140065188
    Abstract: Compositions and methods for stimulating an immune response against a secreted enterohemorragic Escherichia coli (EHEC) antigen are disclosed. The compositions comprise EHEC cell culture supernatants.
    Type: Application
    Filed: November 12, 2013
    Publication date: March 6, 2014
    Applicants: University of Saskatchewan, The University of British Columbia
    Inventors: B. Brett Finlay, Andrew A. Potter
  • Publication number: 20140056940
    Abstract: This invention relates to adjuvant formulations comprising various combinations of triterpenoids, sterols, immunomodulators, polymers, and Th2 stimulators; methods for making the adjuvant compositions; and the use of the adjuvant formulations in immunogenic and vaccine compositions with different antigens. This invention further relates to the use of the formulations in the treatment of animals.
    Type: Application
    Filed: August 29, 2013
    Publication date: February 27, 2014
    Inventors: Paul Joseph Dominowski, Ramasamy Mannar Mannan, Richard Lee Krebs, James Richard Thompson, Tedd Alan Childers, Mary Kathryn Olsen, Robert John Yancey, JR., Risini Dhammika Weeratna, Shucheng Zhang, Cedo Martin Bagi
  • Publication number: 20140050732
    Abstract: The present invention relates a combination for use in the treatment and/or prevention of mastitis containing i) an agonistic anti-CD40 monoclonal antibody or a CD40 ligand or a vector coding for the anti-CD40 antibody or a vector coding for the CD40L; and ii) inactivated or attenuated bacteria selected from the group consisting of Staphylococcus, Streptococcus, Listeria or Escherichia.
    Type: Application
    Filed: March 15, 2013
    Publication date: February 20, 2014
    Inventors: Fabrice Bureau, Hughes Wallemacq, Philippe Boutet, Pierre Lekeux, Laurence Fievez, Julien Pujol
  • Publication number: 20140037716
    Abstract: The present invention relates to immunogenic compositions for modulating the immune system, comprising a therapeutically effective quantity of two or more immuno-active antigenic agents with pathogen-associated molecular patterns (PAMPs) and/or danger-associated molecular patterns (DAMPs) and one or more physiologically acceptable carriers, excipients, diluents or solvents. The immunogenic compositions according to the present invention are used for producing medicaments for preventing and/or treating, and for preventing and/or treating infectious diseases, auto-immune diseases, allergic diseases, inflammation, arthritis, inflammatory diseases, transplant rejection, affections caused by vascular disorders, diseases caused by haemorrhagic or ischaemic cardiovascular accidents, ischaemia, heart attack and haemorrhagia leading to tissue destruction, heart, kidney, respiratory or liver insufficiency, cancer, malign and benign tumours and neoplasia.
    Type: Application
    Filed: March 19, 2012
    Publication date: February 6, 2014
    Inventor: Alexandre Eduardo Nowill
  • Publication number: 20140017313
    Abstract: This invention relates to compositions for delivering one or more active ingredients, and more particularly to compositions, e.g. beads, comprising a matrix material which matrix material comprises a microorganism. In particular, the invention relates to compositions comprising a microorganism selected from live, killed, attenuated and inactivated microorganisms. The matrix material may also comprise a surfactant and may further comprise an adjuvant. The invention further relates to the manufacture and use of such compositions, and to other subject matter.
    Type: Application
    Filed: July 5, 2013
    Publication date: January 16, 2014
    Applicant: Sigmoid Pharma Limited
    Inventors: Ivan Coulter, Bernard Francis McDonald, Vincenzo Aversa, Mónica Rosa
  • Publication number: 20140010844
    Abstract: The invention provides in part methods of treating cancers of a specific organ or tissue by administering a composition that is antigenically specific for one or more microbes that are pathogenic in the specific organ or tissue in which the cancer is situated. The formulations of the invention thereby facilitate activation of an immune response to a cancer in a particular tissue or organ. The compositions may for example include killed or attenuated microbial pathogens, such as whole killed bacterial cells, and may be administered at sites distant from the cancer, for example the skin. In some embodiments, microbial species of endogenous flora that are known to cause infection in the relevant organ or tissue may be used in the formulation of the antigenic compositions. In alternative embodiments, exogenous microbial pathogens that are known to cause infection in the relevant organ or tissue may be used in the formulation of the antigenic compositions.
    Type: Application
    Filed: June 20, 2013
    Publication date: January 9, 2014
    Inventor: Harold David Gunn
  • Publication number: 20130337012
    Abstract: The invention provides in part methods for treating cancers of a specific organ or tissue by administering a composition that is antigenically specific for one or more microbes that are pathogenic in the specific organ or tissue in which the cancer is situated. The compositions may for example include killed or attenuated microbial pathogens, such as whole killed bacterial cells, and may be administered at sites distant from the cancer, for example the skin. In selected embodiments, the invention provides methods for treating a cancer situated in the colon, using formulations of E. coli cells. The administration of the immunogenic compositions may be repeated relatively frequently over a relatively long period of time. In embodiments for intradermal or subcutaneous injection, dosages may be adjusted so that injections reproduce a consistent, visible, inflammatory immune reaction at the site of administration.
    Type: Application
    Filed: May 14, 2013
    Publication date: December 19, 2013
    Applicant: Qu Biologics Inc.
    Inventor: Harold David Gunn
  • Publication number: 20130280301
    Abstract: Compositions and methods of producing vaccines, including methods wherein whole organism vaccines are provided with limited replication abilities, thereby increasing vaccine safety and efficacy, through the use of non-natural, unnatural, or non-naturally encoded amino acids.
    Type: Application
    Filed: July 7, 2013
    Publication date: October 24, 2013
    Inventors: Feng TIAN, Brad HEHLI
  • Publication number: 20130266612
    Abstract: An intraorally administrable vaccine composition useful to be a preventive or therapeutic agent for infectious diseases, and effectively induces a systemic immune response or a mucosal immune response is provided. A vaccine composition for administration to the oral cavity of a human or an animal, the vaccine composition containing at least one antigen derived from an infectious disease, and at least one selected from the group consisting of a toll-like receptor 4 (TLR4) agonist, a toll-like receptor 2/6 (TLR2/6) agonist, and cyclic dinucleotide, or a derivative or salt thereof.
    Type: Application
    Filed: April 3, 2013
    Publication date: October 10, 2013
    Applicants: OSAKA UNIVERSITY, NITTO DENKO CORPORATION
    Inventors: Masahiro FUKASAKA, Arimichi OKAZAKI, Daisuke ASARI, Mitsuhiko HORI, Shizuo AKIRA, Osamu TAKEUCHI
  • Publication number: 20130251748
    Abstract: The present invention relates a method for vaccinating a mammal to produce an antibody against Enterobacteriaceae infection caused by Klebsiella pneumoniae, Salmonella typhi, or E. coli in central nervous system and/or peripheral blood circulation, which comprises administering an effective amount of an OmpK36/homologues or its derivatives to the mammal.
    Type: Application
    Filed: July 10, 2012
    Publication date: September 26, 2013
    Applicant: NATIONAL DEFENSE MEDICAL CENTER
    Inventors: Leung-Kei Siu, Feng-Yee Chang, Yung-Chung Lin, Chang-Phone Fung, Yip-Mei Liu, Jiun-Han Chen, Yu-Kuo Tsai, Pele Choi-Sing Chong, Chih-Hsiang Leng, Shih-Jen Liu, Hsin-Wei Chen
  • Patent number: 8501198
    Abstract: The invention provides in part methods of treating cancers of a specific organ or tissue by administering a composition that is antigenically specific for one or more microbes that are pathogenic in the specific organ or tissue in which the cancer is situated. The formulations of the invention thereby facilitate activation of an immune response to a cancer in a particular tissue or organ. The compositions may for example include killed or attenuated microbial pathogens, such as whole killed bacterial cells, and may be administered at sites distant from the cancer, for example the skin. In some embodiments, microbial species of endogenous flora that are known to cause infection in the relevant organ or tissue may be used in the formulation of the antigenic compositions. In alternative embodiments, exogenous microbial pathogens that are known to cause infection in the relevant organ or tissue may be used in the formulation of the antigenic compositions.
    Type: Grant
    Filed: July 26, 2010
    Date of Patent: August 6, 2013
    Assignee: Qu Biologics Inc.
    Inventor: Harold David Gunn
  • Publication number: 20130177593
    Abstract: The invention provides methods of treating inflammation in a specific organ or tissue of an individual. The method involves determining whether the individual has previously been infected with at least one pathogen that is pathogenic in the specific organ or tissue; and administering to the individual an anti-inflammatory composition comprising antigenic determinants, the antigenic determinants selected or formulated so that together they are specific for the at least one pathogen. The pathogen may be an endogenous or exogenous pathogen, and may further be a bacterial pathogen, a viral pathogen, a fungal pathogen, a protozoan pathogen, or a helminth pathogen.
    Type: Application
    Filed: July 27, 2012
    Publication date: July 11, 2013
    Inventors: Harold David Gunn, Salim Dhanji, Brett Anthony Premack, Michael Tak Huai Chow
  • Patent number: 8481026
    Abstract: Bacteria with improved survival under toxic and oxidative stress and methods of using the same for bioremediation are described. Many bacteria such as Escherichia coli have been found to naturally reduce toxic pollutants into a less toxic form, such as by reducing Chromium (VI) to Chromium (III). Reducing such toxins generates damaging reactive oxygen species, so it is important to find a defense for these bacteria against the associated oxidative stress. Trehalose is a small biomolecule that has been shown to protect bacteria from various types of stress by accumulating within the cells. The present invention is directed to bacteria genetically modified to overexpress trehalose biosynthesis genes. The bacteria demonstrate improved viability when challenged with toxins and oxidative stress. The present invention provides inexpensive and beneficial bacteria and methods for environmental remediation.
    Type: Grant
    Filed: April 16, 2010
    Date of Patent: July 9, 2013
    Inventors: Peter J. Woodruff, Tamlyn M. Frederick
  • Patent number: 8470341
    Abstract: Variants of the pathogenic E. coli ‘AcfD precursor’ have been identified with increased solubility as compared to the native AcfD protein that raise a substantially similar immune response in a subject as the native AcfD protein.
    Type: Grant
    Filed: February 23, 2009
    Date of Patent: June 25, 2013
    Assignee: Novartis AG
    Inventors: Laura Serino, Mariagrazia Pizza, Danilo Gomes Moriel, Maria Rita Fontana
  • Patent number: 8460648
    Abstract: The present invention relates to pharmaceutical compositions suitable for the treatment of chronic diseases associated with the presence of abnormal or an abnormal distribution of microflora in the gastrointestinal tract of a mammalian host, which compositions comprise viable non-pathogenic or attenuated pathogenic Clostridia. The compositions further comprise one or more additional viable non-pathogenic or attenuated pathogenic microorganisms selected from the group consisting of Bacteroides, Eubacteria, Fusobacteria, Propionibacteria, Lactobacilli, anaerobic cocci, Ruminococcus, E.Coli, Gemmiger, Desullomonas, Peptostreptococcus, and fungi. The present invention also provides pharmaceutical compositions suitable for the treatment of the same chronic diseases comprising viable non-pathogenic or attenuated pathogenic Escherichia coli, at least one strain of viable non-pathogenic or attenuated pathoenic Bacteroides and at least one strain of viable non-pathogenic or attenuated pathogenic microorganism.
    Type: Grant
    Filed: July 25, 2001
    Date of Patent: June 11, 2013
    Inventor: Thomas Julius Borody
  • Patent number: 8440203
    Abstract: The present invention discloses methods for protecting newborn calves against neonatal diarrhea by vaccinating pregnant cows and/or pregnant heifers, while minimizing the number of separate occasions producers are required to assemble the cattle.
    Type: Grant
    Filed: November 6, 2009
    Date of Patent: May 14, 2013
    Assignee: Intervet Inc.
    Inventors: Terri L. Wasmoen, Huchappa Jayappa, Randall Gene Davis, Catherine M. Peters
  • Patent number: 8425916
    Abstract: The present invention provides compositions including siderophore receptor polypeptides and porins from gram negative microbes, and preferably, lipopolysaccarhide at a concentration of no greater than about 10.0 endotoxin units per milliliter. The present invention also provides methods of making and methods of using such compositions.
    Type: Grant
    Filed: April 21, 2011
    Date of Patent: April 23, 2013
    Assignee: Epitopix, LLC
    Inventors: Daryll A. Emery, Darren E. Straub
  • Patent number: 8425917
    Abstract: The present invention describes the use of a mutant form of EtxB or CtxB to deliver an agent to a target cell wherein the mutant has GM-1 binding activity; but wherein the mutant has a reduced immunogenic and immunomodulatory activity relative to the wild type form of EtxB or CtxB.
    Type: Grant
    Filed: April 30, 2008
    Date of Patent: April 23, 2013
    Assignee: Hunter Immunology Ltd
    Inventor: Timothy Raymond Hirst
  • Patent number: 8414903
    Abstract: The present invention provides methods and compositions for production of gram-negative bacterial mutants that are defective in intestinal colonization capacity and sensitive to infection by bacteriophage P1. Thus the present invention provides immunogenic compositions for the prevention or attenuation of food- and water-borne illnesses associated with ingestion of bacteria such as enterohemorrhagic Escherichia coli.
    Type: Grant
    Filed: November 20, 2007
    Date of Patent: April 9, 2013
    Assignee: Tufts University
    Inventors: Matthew K. Waldor, Theresa D. Ho
  • Patent number: 8361441
    Abstract: The present invention provides a method for the treatment and/or prevention of bacterial infection caused by Enterobacteriaceae bacteria in central nervous system and/or peripheral blood circulation in a mammal by administering effective amount of outer membrane protein A (OmpA) or its derivatives to a mammal. Also provided are a method for vaccinating a mammal to produce an antibody against bacterial infection caused by Enterobacteriaceae family in central nervous system and/or peripheral blood circulation and a method of detecting or diagnosing bacterial infections caused by Enterobacteriaceae family in central nervous system and/or peripheral blood circulation in a mammal. An antibody and a kit on the basis of the vaccinating method and detecting/diagnosing method are also provided.
    Type: Grant
    Filed: September 29, 2009
    Date of Patent: January 29, 2013
    Assignee: Taipei Medical University
    Inventors: Yi-Yuan Yang, Hsueh-Hsia Wu, Sy-Jye Leu, Neng-Yao Shih, I-Jen Huang, Wen-Shyang Hsieh, Ko-Jiunn Liu, Shih-Yi Huang, Yung-Luen Shih, Chi-Hsin Lee, Yuan-Soon Ho, Shih-Lan Hsu
  • Patent number: 8323668
    Abstract: The present invention describes a novel mechanism of adhesion by flagellated Gram-negative bacteria such as enterotoxigenic Escherichia coli (ETEC), where the bacteria secretes a protein, EtpA which binds to the conserved region of the flagellin protein located at the tip of the flagella. The present invention also discloses that EtpA-mediated interaction and intestinal colonization require interaction with flagellin. Also disclosed herein is a vaccine composition that can be used for either active or passive immunization of mammals for the prevention or treatment of infections caused by flagellated Gram-negative bacteria.
    Type: Grant
    Filed: March 26, 2008
    Date of Patent: December 4, 2012
    Assignee: The University of Tennessee Research Foundation
    Inventor: James M. Fleckenstein
  • Patent number: 8318148
    Abstract: The invention provides strains of bacteria, especially enterotoxigenic E. coli, attenuated by mutations in the genes encoding enterotoxins (LT, ST, EAST1) and optionally further attenuated by deletion of additional chromosomal genes. In addition the invention provides strains of attenuated bacteria expressing immunogenic but non-toxic variants of one or more of these enterotoxins. These bacteria are useful as a vaccine against diarrhoeal disease.
    Type: Grant
    Filed: March 28, 2011
    Date of Patent: November 27, 2012
    Assignee: Acambis Research Limited
    Inventors: Arthur Keith Turner, Judith Greenwood, Jonathan Clive Stephens, Juliet Claire Beavis, Michael James Darsley
  • Publication number: 20120276140
    Abstract: Methods for making and using therapeutic formulations of Proteosome-based immunoactive compositions are provided. The immunogenic compositions, which include Proteosomes and liposaccharides, may be used to elicit or enhance a nonspecific innate immune response to, for example, treat or prevent infectious disease. In addition, after activating the innate immune system, immunogenic compositions further containing an antigen may be used to elicit a specific adaptive immune response. Furthermore, provided are compositions capable of altering hyperreactive responses or inflammatory immune responses, such as allergic reactions. Such compositions may be used as a prophylactic, or in various clinical settings to treat or prevent infectious disease (such as parasite, fungal, bacterial or viral infections), or to alter inappropriate inflammatory immune responses (such as allergic reactions or asthma).
    Type: Application
    Filed: April 26, 2012
    Publication date: November 1, 2012
    Applicant: ID BIOMEDICAL CORPORATION OF QUEBEC
    Inventors: George H. Lowell, David S. Burt, David Hugh Jones, Joseph J. Zimmermann, Clement Rioux
  • Publication number: 20120258135
    Abstract: The invention provides methods of formulating an anti-inflammatory composition for treating inflammatory conditions in a specific organ or tissue. The method involves selecting at least one pathogen that is pathogenic in the specific organ or tissue; producing an antigenic composition comprising antigenic determinants that together are specific for the pathogen; and formulating the antigenic composition for administration as an anti-inflammatory composition capable of eliciting an anti-inflammatory response in the specific organ or tissue. In embodiments of the invention the pathogen may be an endogenous pathogen, such as an endogenous bacterial pathogen. The pathogen may be an exogenous pathogen, such as a bacterial pathogen, viral pathogen, a fungal pathogen, or a helminth pathogen.
    Type: Application
    Filed: January 26, 2012
    Publication date: October 11, 2012
    Inventors: Harold David Gunn, Salim Dhanji, Brett Anthony Premack, Michael Tak Huai Chow
  • Patent number: 8282941
    Abstract: The present invention provides compositions including siderophore receptor polypeptides from gram negative microbes, and preferably, lipopolysaccarhide at a concentration of no greater than about 10.0 endotoxin units per milliliter. The present invention also provides methods of making and methods of using such compositions.
    Type: Grant
    Filed: April 21, 2011
    Date of Patent: October 9, 2012
    Assignee: Epitopix, LLC
    Inventors: Daryll A. Emery, Darren E. Straub
  • Patent number: 8277821
    Abstract: The present invention provides compositions including siderophore receptor polypeptides and porins from gram negative microbes, and preferably, lipopolysaccarhide at a concentration of no greater than about 10.0 endotoxin units per milliliter. The present invention also provides methods of making and methods of using such compositions.
    Type: Grant
    Filed: April 21, 2011
    Date of Patent: October 2, 2012
    Assignee: Epitopix, LLC
    Inventors: Daryll A. Emery, Darren E. Straub
  • Publication number: 20120237544
    Abstract: The present invention relates to a method of coating a spore with one or more therapeutic agents. The present invention also relates to a coated spore obtained by the method of the present invention and the use of the coated spore as a vaccine.
    Type: Application
    Filed: September 21, 2010
    Publication date: September 20, 2012
    Applicant: Royal Holloway and Bedford New College
    Inventors: Simon Michael Cutting, Hong Anh Huynh
  • Publication number: 20120222142
    Abstract: The present application relates to a composition including gut flora-derived extracellular vesicles, and to an animal disease model using same. In addition, the present application relates to a method for using the gut flora-derived extracellular vesicles to efficiently search for a candidate drug which may prevent or treat diseases that occur due to gut flora-derived extracellular vesicles, and to a vaccine which can efficiently prevent or treat infections caused by gut flora or diseases that occur due to gut flora-derived extracellular vesicles. Further, the development of diagnostic technology to discover, using the gut flora-derived extracellular vesicles of the present application, the etiology of diseases that occur due to gut flora-derived extracellular vesicles, can be achieved.
    Type: Application
    Filed: July 20, 2010
    Publication date: August 30, 2012
    Applicant: AEON MEDIX INC.
    Inventors: Yoon Keun Kim, Yong Song Gho, Kyoung Su Park, Bok Sil Hong, Ji Hyun Kim, You Sun Kim, Won Hee Lee, Jung Wook Kim, Dae-Kyum Kim
  • Publication number: 20120189572
    Abstract: The invention provides therapeutics and methods to induce a mammalian host, including a human, to produce antibodies, which agonize death receptors and cause the apoptotic death of target cells within the host's body. The therapeutics are vaccine compositions, including genetic vaccines encoding death receptor antigens of the tumor necrosis factor receptor family. Also provided are means and methods for overcoming host immunological tolerance to death receptors. The vaccines are useful against cancer cells and other death receptor bearing target cells within the host, and can be used in both therapeutic and prophylactic settings. The vaccines are also useful for diagnostic testing of the immunocompetence of a host.
    Type: Application
    Filed: November 6, 2009
    Publication date: July 26, 2012
    Inventors: Wei-Zen Wei, Gen Sheng Wu, Marie P. Piechocki, Richard F. Jones